After five decades of use, flow cytometry is entrenched in biomedical science. Besides enabling the quick processing of cells in suspension, flow cytometry provides quantitative results across ...
TD2 Oncology delivers fully integrated preclinical, regulatory, and clinical services for cancer drug development. In response to advances in In Vivo CAR-T engineering, TD2 Oncology launches flow ...
FRANKLIN LAKES, N.J. & SAN DIEGO--(BUSINESS WIRE)--BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation ...
Over the past decade, flow cytometry has undergone transformative advancements, notably with the adoption of spectral flow cytometry and the emergence of next-generation imaging cytometers. These ...
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial Invivoscribe Inc., a ...
Genetically-humanized FcRn mice provide translational pharmacokinetics (PK) and pharmacodynamics (PD) data for antibody-based therapeutics. The image illustrates a therapeutic antibody (blue) adhering ...
This article is based on a poster originally authored by Sophie Snow, Kira Freeman, Zaynab Isseljee, Alice Brankin and Christine Sanfelice, which was presented at ELRIG Drug Discovery 2024 in ...
Cytek Biosciences, Inc. has launched the Cytek® Muse® Micro, an enhanced version of its original Guava® Muse® cell analyzer, aimed at making advanced cell analysis more accessible and affordable. The ...
Technology Networks spoke with Dr. Jean-Marc Busnel, principal investigator and senior staff research scientist at Beckman Coulter Life Sciences, to learn about the BAT and how it is being translated ...
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results